Coherus Biosciences | CHRS - Текущие обязательства





Текущие обязательства Изменить Дата
AbbVie USD 43.29B 3.9B 2025-12
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Akebia Therapeutics USD 162.94M 29.56M 2025-12
ALKERMES USD 599.5M 56.06M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amarin USD 179.64M 14.82M 2026-03
Amgen USD 24.96B 534M 2026-03
Baxter International USD 3.69B 723M 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Coherus Biosciences USD 140.39M 231.91M 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Fujifilm JPY 1.2T 44.21B 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
Ironwood Pharmaceuticals USD 242.5M 9.98M 2025-09
Merck USD 26.94B 1.38B 2026-03
Myriad Genetics USD 133.8M 14.2M 2025-12
Pacira USD 108.79M 11.8M 2026-03
Perrigo USD 1.01B 132.4M 2025-12
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 968.43M 102.18M 2025-12
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Teva Pharmaceutical Industries USD 13.53B 76M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03
Xencor USD 95.91M 9.42M 2025-12
Zoetis USD 2.24B 428M 2025-12